The Anti-obesity and Anti-inflammatory Effects of “LICONINE^™”, an Extract of Glycyrrhiza Uralensis, on Diet-induced Obese Mice and 3T3-L1 Mouse Adipocytes

Yuka Sasakawa^{1, 2,} , Akari Kominami^{1, 2}, Michiyo Abe^{1, 2}, Kaori Yamamoto², Mayumi Nakao², Fumiko Nakaoka², Shigetoshi Okumura^{2, 3}, Lekh Raj Juneja^{2, 3} and Jun Kunisawa¹

¹Laboratory of Vaccine Materials, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan

²MG Pharma Inc., Osaka, Japan

³ROHTO Pharmaceutical Co., Ltd., Osaka, Japan

Cite this paper:
Yuka Sasakawa, Akari Kominami, Michiyo Abe, Kaori Yamamoto, Mayumi Nakao, Fumiko Nakaoka, Shigetoshi Okumura, Lekh Raj Juneja and Jun Kunisawa. The Anti-obesity and Anti-inflammatory Effects of “LICONINE^™”, an Extract of Glycyrrhiza Uralensis, on Diet-induced Obese Mice and 3T3-L1 Mouse Adipocytes. Journal of Food and Nutrition Research. 2017; 5(10):781-788. doi: 10.12691/jfnr-5-10-9

Abstract

The anti-obesity effect of Glycyrrhiza uralensis (Ural licorice) extract at the intake level of low risk has not been clarified. In the present study, the anti-obesity effects of Ural licorice, its extracts, its fractions and Glycyrrhizic acid at intake levels of low risk were examined in high-fat high-sucrose (HFS) diet-induced obese mice. Ural licorice extract, which was given the brand name “LICONINE^™,” was the most effective extract; it decreased body weight, visceral fat weight, number of adipocyte crown-like structures, and adipocyte size in visceral fat. Low doses of LICONINE also had anti-obesity effects. The terpenoid fraction, but not flavonoid fraction, of LICONINE had an anti-obesity effect that did not depend exclusively on Glycyrrhizic acid. Next, we examined the effects of Ural licorice extracts, LICONINE fractions, and constituents of LICONINE terpenoid fraction on production of monocyte chemoattractant protein-1 in 3T3-L1 mouse adipocytes. LICONINE and its terpenoid fraction had anti-obesity and anti-inflammatory effects in both HFS diet-induced obese mice and 3T3-L1 adipocytes. Our results demonstrate for the first time that Licorice saponin G2, Licorice saponin H2, and Glycyrrhizic acid (all constituents of LICONINE terpenoid fraction) had anti-inflammatory effects in 3T3-L1 adipocytes. In summary, at the intake level of low risk (human equivalent to less than 1 g licorice per day), LICONINE is an effective extract of Ural licorice and the terpenoid fraction is an effective fraction of LICONINE for treating obesity. Further research is needed to identify the mechanism underlying the anti-obesity and anti-inflammatory effects of LICONINE and its terpenoid fraction.

Keywords:
glycyrrhiza uralensis ural licorice extract LICONINE high-fat high-sucrose diet-induced obese mice obesity 3T3-L1 mouse adipocytes monocyte chemoattractant protein-1

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Ministry of Health, Labour and Welfare, Japan, “The Japanese Pharmacopoeia 17th edition,” The MHLW Ministerial Notification No. 64, March. 2016.
[2]	Ministry of Health, Labour and Welfare, Japan, “About handling of medical supplies contain glycyrrhizic acid,” The MHLW Ministerial Notification No. 158, February. 1978 (in Japanese).
[3]	Nakagawa, K., Kishida, H., Arai, N., Nishiyama, T. and Mae, T., “Licorice flavonoids suppress abdominal fat accumulation and increase in blood glucose level in obese diabetic KK-Ay mice,” Biological and Pharmaceutical Bulletin, 27 (11). 1775-1778. 2004.
[4]	Tominaga, Y., Mae, T., Kitano. M., Sakamoto, Y., Ikematsu, H. and Nakagawa, K., “Licorice flavonoid oil effects body weight loss by reduction of body fat mass in overweight-subjects,” Journal of Health Science, 52 (6). 672-683. 2006.
[5]	Aoki, F., Honda, S., Kishida, H., Kitano, M., Arai, N., Tanaka, H., Yokota, S., Nakagawa, K., Asakura, T., Nakai, Y. and Mae, T., “Suppression by licorice flavonoids of abdominal fat accumulation and body weight gain in high-fat diet-induced obese C57BL/6J mice,” Bioscience Biotechnology and Biochemistry, 71 (1). 206-214. 2007.
[6]	Tominaga, Y., Nakagawa, K., Mae, T., Kitano, M., Yokota, S., Arai, T., Ikematsu, H. and Inoue, S., “Licorice flavonoid oil reduces total body fat and visceral fat in overweight subjects: A randomized, double-blind, placebo-controlled study,” Obesity Research & Clinical Practice, 3 (3). 169-178. 2009.
[7]	Armanini, D., De, Palo, C.B., Mattarello, M.J., Spinella, P., Zaccaria, M., Ermolao, A., Palermo, M., Fiore, C., Sartorato, P., Francini-Pesenti, F. and Karbowiak, I., “Effect of licorice on the reduction of body fat mass in healthy subjects,” Journal of Endocrinological Investigation, 26 (7). 646-650. 2003.
[8]	Saunier, E.F., Vivar, O.I., Rubenstein, A., Zhao, X., Olshansky, M., Baggett, S., Staub, R.E., Tagliaferri, M., Cohen, I., Speed, T.P., Baxter, J.D. and Leitman, D.C., “Estrogenic plant extracts reverse weight gain and fat accumulation without causing mammary gland or uterine proliferation,” PLoS One, 6 (12). e28333. 2011.
[9]	Honda, H., Nagai, Y., Matsunaga, T., Okamoto, N., Watanabe, Y., Tsuneyama, K., Hayashi, H., Fujii, I., Ikutani, M., Hirai, Y., Muraguchi, A. and Takatsu, K., “Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation,” Journal of Leukocyte Biology, 96(6). 1087-1100. 2014.
[10]	Watanabe, Y., Nagai, Y., Honda, H., Okamoto, N., Yamamoto, S., Hamashima, T., Ishii, Y., Tanaka, M., Suganami, T., Sasahara, M., Miyake, K. and Takatsu, K., “Isoliquiritigenin Attenuates Adipose Tissue Inflammation in vitro and Adipose Tissue Fibrosis through Inhibition of Innate Immune Responses in Mice,” Scientific Reports, 6. 23097. 2016.
[11]	Ko, B.S., Jang, J.S., Hong, S.M., Sung, S.R., Lee, J.E., Lee, M.Y., Jeon, W.K. and Park, S., “Changes in components, glycyrrhizin and glycyrrhetinic acid, in raw Glycyrrhiza uralensis Fisch, modify insulin sensitizing and insulinotropic actions, Glycyrrhizin,” Bioscience Biotechnology and Biochemistry, 71 (6). 1452-1461. 2007.
[12]	Geary, R.C., “Testing for normality,” Biometrika, 34 (3-4). 209-242. 1947.
[13]	Ryan, T.A., “Multiple comparisons in psychological research,” Psychological Bulletin, 56 (1). 26-47. 1959.
[14]	Ryan, T.A., “Significance tests for multiple comparison of proportions, variances, and other statistics,” Psychological Bulletin, 57. 318-328. 1960.
[15]	Ozaki, M., Fujita, T., Kumagai, Y. and Otani, Y., “A retrospective study for determining the starting dose in first-in-human studies on Japanese healthy volunteers,” Japanese Journal of Clinical Pharmacology and Therapeutics, 37 (3). 119-126. 2006.
[16]	Jayaprakasam, B., Doddaga, S., Wang, R., Holmes, D., Goldfarb, J. and Li, X.M., “Licorice flavonoids inhibit eotaxin-1 secretion by human fetal lung fibroblasts in vitro,” Journal of Agricultural and Food Chemistry, 57 (3). 820-825. 2009.
[17]	Revelo, X.S., Luck, H., Winer, S. and Winer, D.A., “Morphological and inflammatory changes in visceral adipose tissue during obesity,” Endocrine Pathology, 25 (1). 93-101. 2014.
[18]	Bremer, A.A., Devaraj, S., Afify, A. and Jialal, I., “Adipose tissue dysregulation in patients with metabolic syndrome,” The Journal of Clinical Endocrinology & Metabolism, 96 (11). E1782- E1788. 2011.
[19]	Shaul, M.E., Bennett, G., Strissel, K.J., Greenberg, A.S. and Obin, M.S., “Dynamic, M2-like remodeling phenotypes of CD11c+ adipose tissue macrophages during high-fat diet--induced obesity in mice,” Diabetes, 59 (5). 171-181. 2010.
[20]	Gustafson, B., “Adipose tissue, inflammation and atherosclerosis,” Journal of Atherosclerosis and Thrombosis, 17 (4). 332-341. 2010.
[21]	Baker, R.G., Hayden, M.S. and Ghosh, S., “NF-κB, inflammation, and metabolic disease,” Cell Metabolism, 13 (1). 11-22. 2011.
[22]	Kanda, H., Tateya, S., Tamori, Y., Kotani, K., Hiasa, K., Kitazawa, R., Kitazawa, S., Miyachi, H., Maeda, S., Egashira, K. and Kasuga, M., “MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity,” Journal of Clinical Investigation, 116 (6). 1494-1505. 2006.
[23]	Minegishi, Y., Haramizu, S., Misawa, K., Shimotoyodome, A., Hase, T. and Murase, T., “Deletion of nuclear factor-κB p50 upregulates fatty acid utilization and contributes to an anti-obesity and high-endurance phenotype in mice,” Am J Physiol Endocrinol Metab, 309 (6). E523-533. 2015.